LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Arthur Klausner will be a panelist at "The Venture Prognosis - what's driving investment preferences?" at the Life Sciences & Healthcare Venture Summit on October 23, 2007 in NYC
News | 10. 23. 2007
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.